Drug Index

Nelfinavir

 
print

Mechanism :

Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in non-infectious, immature viral particles.


Indication :

• Treatment of HIV


Contraindications :

Hepatic impairment, Child-Pugh Class B or C

Hypersensitivity


Dosing :

2 to <13 years: 45 to 55 mg/kg orally 2 times a day or 25 to 35 mg/kg orally thrice a day. Maximum dose: 2500 mg/day.

>13 years: 1250 mg orally twice a day (preferred regimen) or 750 mg orally 3 times a day.


Adverse Effect :

Serious Reactions: Hyperglycemia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, pancreatitis, hepatotoxicity, leukopenia, thrombocytopenia, anemia, hypersensitivity reaction.

Common Reactions: Diarrhea, nausea, anorexia, abdominal pain, flatulence, rash, neutropenia, leukopenia, hyperglycemia, lipodystrophy, elevated ALT/AST.


Interaction :

Abacavir: The serum concentration of Abacavir may be decreased.
Abiraterone: Strong CYP3A4 inhibitors may increase levels of abiraterone.
Acenocoumarol, Anisindione: Nelfinavir may increase the anticoagulant effect of acenocoumarol.
Alprazolam: Nelfinavir may increase the effect of the alprazolam.
Amiodarone: Nelfinavir may increase the effect and toxicity of amiodarone.
Aprepitant: This CYP3A4 inhibitor increases the effect and toxicity of Aprepitant.
Astemizole: Increased risk of cardiotoxicity and arrhythmias.
Atorvastatin, Bromazepam: Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism.
Cabazitaxel: Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel.
Chlordiazepoxide: Nelfinavir may increase the effect of the benzodiazepine, chlordiazepoxide.
Cisapride: Increased risk of cardiotoxicity and arrhythmias.
Clorazepate, Clonazepam: The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepines.
Midazolam: The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, midazolam.
Pimozide: Nelfinavir increases the effect and toxicity of pimozide.
Ponatinib: Strong CYP3A4 inhibitors may increase levels of ponatinib.
Quazepam: The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, quazepam.
Solifenacin: This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism.
Tamoxifen: Nelfinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism.
Tamsulosin: Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate.
Telaprevir: Telaprevir increases levels by affecting CYP3A4 metabolism.
Telithromycin: Nelfinavir may increase the plasma concentration of Telithromycin.
Temsirolimus: Nelfinavir may inhibit the metabolism and clearance of Temsirolimus.
Teniposide: The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate.
Terfenadine: Increased risk of cardiotoxicity and arrhythmias
Tiagabine: The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate.
Tolterodine: Nelfinavir may decrease the metabolism and clearance of Tolterodine.
Topotecan: The p-glycoprotein inhibitor, Nelfinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan.
Tramadol: Nelfinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Triazolam, Trazodone: The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, triazolam.
Trimipramine: The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate.
Vardenafil: Nelfinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil.
Vemurafenib: Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
Verapamil, Venlafaxine: Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Verapamil, a CYP3A4 substrate, by decreasing its metabolism and clearance.
Vinblastine, Vinorelbine, Vincristine: Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism.
Voriconazole: Nelfinavir may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of nelfinavir by decreasing its metabolism.
Warfarin: The protease inhibitor, nelfinavir, may increase the anticoagulant effect of warfarin.
Zopiclone, Zonisamide, Zolpidem: Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism.


07/18/2019 12:09:56 Nelfinavir
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0